Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
6(32%)
Results Posted
40%(2 trials)
Terminated
1(5%)

Phase Distribution

Ph phase_3
1
5%
Ph early_phase_1
1
5%
Ph not_applicable
2
11%
Ph phase_1
2
11%
Ph phase_2
11
58%

Phase Distribution

3

Early Stage

11

Mid Stage

1

Late Stage

Phase Distribution17 total trials
Early Phase 1First-in-human
1(5.9%)
Phase 1Safety & dosage
2(11.8%)
Phase 2Efficacy & side effects
11(64.7%)
Phase 3Large-scale testing
1(5.9%)
N/ANon-phased studies
2(11.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

6

trials recruiting

Total Trials

19

all time

Status Distribution
Active(9)
Completed(5)
Terminated(2)
Other(3)

Detailed Status

Completed5
Recruiting4
Not yet recruiting3
unknown3
Active, not recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
19
Active
6
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (5.9%)
Phase 12 (11.8%)
Phase 211 (64.7%)
Phase 31 (5.9%)
N/A2 (11.8%)

Trials by Status

not_yet_recruiting316%
recruiting421%
active_not_recruiting211%
terminated15%
withdrawn15%
completed526%
unknown316%

Recent Activity

Clinical Trials (19)

Showing 19 of 19 trials
NCT07148843Phase 2

Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving

Not Yet Recruiting
NCT05836857

The Use of Cannabis (Marijuana) and Cannabidiol (CBD) Among Cancer Patients: A Pilot Study

Active Not Recruiting
NCT05753007Phase 2

A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients

Terminated
NCT07434973Phase 3

Stratification and Treatment in Early Psychosis Study - PROMOTE

Not Yet Recruiting
NCT02556008

Cannabidiol for Pediatric Epilepsy (Compassionate Use)

Unknown
NCT04567784Phase 2

Neuroimaging and CBD for Opioid Use Disorder

Completed
NCT07167446Early Phase 1

Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy

Recruiting
NCT04992624Phase 2

Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee

Recruiting
NCT05020028Phase 2

Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis

Recruiting
NCT05269628Phase 2

Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype

Recruiting
NCT06994520Phase 2

Efficacy of Topical Cannabidiol for Eczema

Active Not Recruiting
NCT04754399Phase 2

Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias

Completed
NCT06695195Phase 1

A Randomized Controlled Trial of Oral CBD for the Treatment of Upper Extremity Musculoskeletal Pain

Not Yet Recruiting
NCT06286839Not Applicable

Study of Cannabidiol (CBD) in Healthy Volunteers

Completed
NCT05387148Phase 2

The Efficacy and Neurobehavioural Mechanism of Cannabidiol (CBD) for Alcohol Dependence

Unknown
NCT04881539Not Applicable

CBD, Immune Function, and Neural Health

Completed
NCT03883360Phase 2

Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis

Withdrawn
NCT04193631Phase 1

Low Dose of Cannabidiol (CBD) to Treat Mild to Moderate Musculoskeletal Pain

Completed
NCT02255292Phase 2

A Study: Pure CBD as Single-agent for Solid Tumor.

Unknown

All 19 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
19